更新日：2022年10月27日

奥山上席専門研究員が当研究所の人工アミノ酸製剤（MeAIB）を用いた形質細胞性腫瘍へのPETの評価について世界核医学会で発表しました。

• 日付
  2022年9月20日
• 発表日
  2022年9月7日～11日
• 学会名
  The 13th World Federation of Nuclear Medicine and Biology (世界核医学会）
• 開催地
  京都国際会議場
• 演題
  C-11 MeAIB PET/CT in patients with plasma cell tumor
• 演者
  奥山上席専門研究員
• 要旨
  【Background/Aims】It is known that FDG-PET frequently fails to visualize plasma cell tumor (PCT). In this paper, we evaluated the utility ofC-11-α-methylamino isobutyric PET/CT. 【Methods】Nineteen patients with PCT,multiple myeloma (MM) -13、Mproteinemia without myeloma (MP) -6
  ,underwent both FDG and MeAIB PET/CT with at most 10 days interval between the two PET scans. Patient-based and lesion-based evaluation on the PET/CT findings using each tracer were performed. The intensity of diffuse marrow uptake,and the number and the SUV of focal accumulation were evaluated.
  In 4 cases with MM, the PET scans were repeated after chemotherapy and evaluated the utility compared to other laboratory data. This study was performed under an institutional review board-approved protocol, and written informed consents were obtained from all patients.
  【Results】In cases with MM, MeAIB visualized more focal lesions than FDG in 8 of 13 cases including many sites without no apparent lytic changes on CT scan while FDG mainly visualized
  significant uptake on the lytic cites. Intense or moderate diffuse bone marrow accumulation was seen in 9 and 5 patients with MM on MeAIB and FDG, respectively, and in 4 and 2 cases with MP.
  MeAIB visualized residual lesions after chemotherapy as well while M protein or Bence-Jones protein had disappeared, that helped the physician to determine the treatment. On the other hand, abnormal uptakes were seen at fracture sites on healed old MM lesions.
  【Conclusions】MeAIB-PET, an amino acid tracer transported through system A transporter, is superior to FDG-PET in visualizing MM lesions.